Premier Research appoints Anthony Orlando and Bruce C. Stouch to New Senior Management Positions
Premier Research Group plc (AIM: PRG) ("Premier ResearchÅh, ÅgCompany" or ÅgGroupÅh), the international pharmaceutical services group today announces the appointment of Anthony Orlando, Ph.D. and Bruce C. Stouch, Ph.D. to senior management positions in Premier Research.
PHILADELPHIA, May 10 -- Premier Research Group plc (AIM: PRG) ("Premier Research," "Company" or "Group), the international pharmaceutical services group today announces the appointment of -- Anthony Orlando, Ph.D. and Bruce C. Stouch, Ph.D. to senior management positions in Premier Research.
Dr Anthony Orlando, Ph.D. has joined the US Operations of Premier Research Group plc in the new position of Executive Director, Data Operations. Dr. Orlando brings an exceptional background in Biostatistics and Data Management over the past thirty years including key roles in pharmaceutical companies, the National Center for Toxicological Research/FDA and at major contract research organizations. He most recently joined the company from his position as Vice President, Biostatistics at SFBC New Drug Services. Dr. Orlando holds a Ph.D. in Biometry from Yale University has co-authored many papers in his area of expertise and has supported several drug NDAs for a variety of indications. He will be responsible for US data management, programming and biostatistics for Premier Research.
In addition to Dr. Orlandofs position, Premier Research also is pleased to announce that Bruce C. Stouch, Ph.D. has taken the international position of Chief Scientific Officer for the company. In Dr. Stouchfs new role, he will lead the company's efforts supporting expert FDA/statistical clinical design and analysis capabilities. He will also establish and expand the companyfs new initiative into Bayesian monitoring and analysis methods. Dr. Stouch has over 15 years of biostatistics experience in pharmaceuticals.
For 12 years, Dr. Stouch held the position of Director of Biostatistics and Scientific Data Management at Johnson & Johnson in Exton, PA, where he was responsible for strategic development and implementation of pharmacoeconomic models of emerging technologies in several therapeutic areas. Dr. Stouch has been involved in over two dozen publications and acknowledgements. He holds an academic appointment at the Philadelphia College of Medicine as Director, Biostatistics and Clinical Epidemiology. Dr. Stouch received his Ph.D. in Biostatistics and Epidemiology from Jefferson Medical College in 1997 through a program sponsored by Johnson & Johnson, and trained in post-graduate studies from Temple University, Jefferson Medical College, and Harvard School of Public Health.
Dr Simon Yaxley, CEO of Premier Research Group plc, commented: gWe are proud and pleased to announce the significant strengthening of our data management and statistics capabilities in the US Operations. We also believe that Tony and Bruce place our company at the forefront of trial design, monitoring and analysis methods worldwide.
About Premier Research
Premier Research Group plc is a contract research organisation focused on the design, management and reporting of all phases of clinical trials on behalf of pharmaceutical and biotechnology companies. The Company specialises in oncology, central nervous system, paediatrics and anti-infectives.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
